Lakefront Biotherapeutics NV LKFT
33.45 USD -0.11 (-0.33%)
At closeNov 6, 2026, 4:00 PM EST
33.45 0.00 0.00%
After hours · Nov 6, 4:00 PM ET
32.27 Day range 33.60
26.08 52-week range 34.64
- YTD
- +2.29%
- 1 year
- +7.21%
News
globenewswire.com Lakefront Biotherapeutics Announces Poster Presentation at the 2026 American Society of Hematology Meeting Gamgertamig data from ongoing Phase 1b studies suggest potential to retain remission after B cell reconstitution, maintained in the absence of background therapy for autoimmune cytopenias, consistent…
globenewswire.com Lakefront Biotherapeutics Welcomes Dr. Mehdi Shahidi to its Board of Directors Dr. Shahidi brings extensive drug development experience, regulatory success, and transformative operational expertise to the Board
benzinga.com Bank Of America Crosses Below Threshold Of 10% Of Lakefront's Voting Rights, Transparency Notification Shows Pursuant to Belgian transparency legislation1, Lakefront received a transparency notification, from Bank of America Corporation on October 6, 2026. The notification indicates that Bank of America…
benzinga.com This 3M Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday Analysts upgraded First Financial, 3M, Synopsys, Humana and Stem, raising targets for four while maintaining Stem’s $7 target.
benzinga.com Crude Oil Gains 1%; Cintas Earnings Top Views U.S. stocks fell Wednesday, led by a 1.1% Nasdaq drop. Cintas beat estimates and raised guidance; oil gained while gold, silver and copper declined.
benzinga.com TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securitize, Lakefront and others also gained.
benzinga.com This Editas Medicine Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday Analysts upgraded Microsoft, Graphic Packaging, Editas Medicine and Lakefront Biotherapeutics, with mixed price-target changes.- benzinga.com RBC Capital Upgrades Lakefront Biotherapeutics to Outperform, Raises Price Target to $45 RBC Capital analyst Brian Abrahams upgrades Lakefront Biotherapeutics (NASDAQ:LKFT) from Sector Perform to Outperform and raises the price target from $26 to $45.
benzinga.com Bank Of America Raises Lakefront Biotherapeutics Stake Above To 10.11% Lakefront Biotherapeutics NV ((Euronext &, NASDAQ:LKFT) received a transparency notification from Bank of America.Pursuant to Belgian transparency legislation1, Lakefront received a transparency…
benzinga.com Morgan Stanley Maintains Equal-Weight on Lakefront Biotherapeutics, Lowers Price Target to $26 Morgan Stanley analyst Judah Frommer maintains Lakefront Biotherapeutics (NASDAQ:LKFT) with a Equal-Weight and lowers the price target from $30 to $26.
benzinga.com RBC Capital Maintains Sector Perform on Lakefront Biotherapeutics, Lowers Price Target to $26 RBC Capital analyst Brian Abrahams maintains Lakefront Biotherapeutics (NASDAQ:LKFT) with a Sector Perform and lowers the price target from $28 to $26.
benzinga.com Lakefront Biotherapeutics Q2 EPS $0.29 Beats $(13.52) Estimate, Sales $21.624M Beat $7.210M Estimate Lakefront Biotherapeutics (NASDAQ:LKFT) reported quarterly earnings of $0.29 per share which beat the analyst consensus estimate of $(13.52) by 102.14 percent. This is a 120 percent increase over…
benzinga.com Lakefront Biotherapeutics Receives Transparency Notification As Madison Avenue Partners Crossed Above 5% Of Voting Rights Lakefront Biotherapeutics NV ((Euronext &, NASDAQ:LKFT) received a transparency notification from Madison Avenue Partners.Pursuant to Belgian transparency legislation1, Lakefront received a…
benzinga.com Lakefront Biotherapeutics Repurchases 38,537 Of Its Own Shares Through June 9 - June 12 Lakefront Biotherapeutics NV ((Euronext &, NASDAQ:LKFT) ("Lakefront") announces that it has repurchased 38,537 Lakefront shares between June 9, 2026 and June 12, 2026- benzinga.com Lakefront Biotherapeutics Says Bank Of America Raised Its Stake To 9.3% Through Voting Rights And Financial Instruments Lakefront Biotherapeutics NV ((Euronext &, NASDAQ:LKFT) received a transparency notification from Bank of America.Pursuant to Belgian transparency legislation1, Lakefront received a transparency…